Clinical Trial Search block Test

AALL1621, A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

AALL1621

  • Condition(s): Acute Lymphoblastic Leukemia (ALL), Leukemia & Lymphoma, Recurrent and/or Refractory
  • Phase: II
  • Clinicaltrials.gov ID: NCT02981628

What is the goal of the study?

AALL1621 is a group-wide single-arm phase 2 study to evaluate the toxicity profile and preliminary efficacy of inotuzumab ozogamicin (InO) in pediatric patients with CD22-positive B-lymphoblastic leukemia (B-ALL) that is refractory or in second or greater relapse. InO is an antibody-drug conjugate composed of a humanized IgG subtype 4 monoclonal CD22-targeted antibody linked to calicheamicin, a potent anti-tumor antibiotic. InO demonstrated exceptional activity in relapsed or refractory B-ALL in adults.

Who can participate in the study?

Everyone

Study Team: